Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization
© Han et al.; licensee BioMed Central Ltd. 2014
Received: 30 November 2013
Accepted: 12 January 2014
Published: 15 January 2014
We previously reported a PI3K inhibitor S14161 which displays a promising preclinical activity against multiple myeloma (MM) and leukemia, but the chiral structure and poor solubility prevent its further application.
Six S14161 analogs were designed based on the structure–activity relationship; activity of the compounds in terms of cell death and inhibition of PI3K were analyzed by flow cytometry and Western blotting, respectively; anti-myeloma activity in vivo was performed on two independent xenograft models.
Among the six analogs, BENC-511 was one of the most potent compounds which significantly inhibited PI3K activity and induced MM cell apoptosis. BENC-511 was able to inactivate PI3K and its downstream signals AKT, mTOR, p70S6K, and 4E-BP1 at 1 μM but had no effects on their total protein expression. Consistent with its effects on PI3K activity, BENC-511 induced MM cell apoptosis which was evidenced by the cleavage of Caspase-3 and PARP. Notably, addition of insulin-like growth factor 1 and interleukin-6, two important triggers for PI3K activation in MM cells, partly blocked BENC-511-induced MM cell death, which further demonstrated that PI3K signaling pathway was critical for the anti-myeloma activity of BENC-511. Moreover, BENC-511 also showed potent oral activity against myeloma in vivo. Oral administration of BENC-511 decreased tumor growth up to 80% within 3 weeks in two independent MM xenograft models at a dose of 50 mg/kg body weight, but presented minimal toxicity. Suppression of BENC-511 on MM tumor growth was associated with decreased PI3K/AKT activity and increased cell apoptosis.
Because of its potent anti-MM activity, low toxicity (LD50 oral >1.5 g/kg), and easy synthesis, BENC-511 could be developed as a promising agent for the treatment of MM via suppressing the PI3K/AKT signaling pathway.
KeywordsPhosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway BENC-511 S14161 Multiple myeloma Drug discovery
The phosphatidylinositol 3-kinases (PI3Ks) are a family of intracellular lipid enzymes that phosphorylate the 3′-OH group at the inositol ring of phosphatidylinositol and convert PI(4,5)P2 to PI(3,4,5)P3 [1, 2]. The latter then acts as a secondary messenger that mediates the AKT activation and a series of downstream signals that are responsible for various cell activities, such as tissue factor expression and coagulation , cell proliferation and survival . Dysregulation of the PI3K/AKT signaling pathway is frequently seen in many cancer types [5–7], including hematological malignancies, such as leukemia , lymphoma , and multiple myeloma (MM) [10, 11]. Overactivation of PI3K/AKT confers chemoresistance and poor outcomes, while knockdown of PI3K or AKT leads to cancer cell death [5, 12, 13]. Therefore, the PI3K/AKT pathway is regarded as an ideal target for cancer therapy [5–7]. Actually, more and more PI3K/AKT inhibitors have been identified, of which some have been successfully moved into clinical evaluation [14, 15].
MM is a malignancy of plasma cells and it accounts for more than 10% of all hematological cancers and 2% of annual cancer-related death . It is believed that the PI3K/AKT pathway is particularly pertinent for MM growth and therapy. There are four members in the Class I PI3K family, namely, PI3Kα, β, δ and γ, all of which are overactivated in MM cell lines and primary myeloma patient cells . Moreover, phosphatase and tensin homolog (PTEN), the critical negative modulator of PI3K signaling, is frequently deleted or inactivated by mutation in MM cells . Activation of PI3Ks in MM is associated with growth factors such as insulin-like growth factor 1 (IGF-1) and cytokines such as interleukin-6 (IL-6), both of which are highly expressed in MM cells . In an analysis of AKT activity in MM cells, the expression of phosphorylated-AKT (S473) was found in 16 of 18 patients, which indicates constitutively phosphorylated-AKT in primary MM cells . In addition, this key signaling is also an indicator of unfavorable outcomes of myeloma patients . Moreover, inhibition of PI3K/AKT leads to MM apoptosis. Therefore, PI3K/AKT is an ideal target for anti-myeloma drug discovery. Many inhibitors of the PI3K/AKT signaling pathway, such as CAL-101, NVP-BKM120, and Perifosine have been developed for MM therapy and are now evaluated in clinical trials [21–23]. However, there are no approved PI3K inhibitors available for MM therapy due to collective efficacy and/or safety issues, novel PI3K inhibitors are in demand.
We recently identified S14161 as an inhibitor of pan-Class I PI3K isoforms by a high throughput screening strategy . S14161 induces apoptosis in myeloma and leukemia cell lines as well as primary patient samples. Notably, S14161 is also effective in leukemia xenograft models . Given its potent antileukemia and antimyeloma activity and minimal toxicity, S14161 can serve as a new lead for cancer drug development. To improve its physical and chemical properties, such as solubility and chirality, we designed a series of analogs of S14161 based on the structure-activity relationship, and identified BENC-511 as a more potent inhibitor of PI3K signaling for the treatment of MM.
BENC-511 displays potent inhibitory effects on AKT activation
To further characterize the effect of BENC-511 on AKT activation, BENC-511 was added to RPMI-8226, LP1, and OPM2 cells from 1 to 4 μM for 24 hours. Western blotting analysis revealed that AKT phosphorylation was inhibited at both T308 and S473 sites in a concentration- and time- dependent manner (Figure 1D and E). Because the full activation of AKT depends on both T308 and S473 sites, these results suggested that BENC-511 fully suppressed AKT activation at high concentrations.
BENC-511 suppresses AKT activation triggered by IGF-1 and IL-6
BENC-511 downregulates PI3K/AKT downstream signals
BENC-511 induces MM cell apoptosis
BENC-511 induces MM cell apoptosis in the presence of IL-6 or IGF-1
IL-6 and IGF-1 can be secreted by the bone marrow stromal cells (BMSC) and regulate proliferation and survival of MM cells by regulating the PI3K/AKT signaling pathway via autocrine and/or paracrine manners [26, 28]. To further demonstrate the effects of IGF-1 and IL-6 on MM cell growth, MM cell line OPM2 was cultured alone or in the presence of human stromal cell line HS-5. PARP cleavage assay revealed that stromal cells conferred resistance to BENC-511 because the presence of stromal cells attenuated the effects of BENC-511 on PARP cleavage and AKT activation in MM cells (Figure 6B). This further demonstrated that BENC-511 induced MM cell apoptosis in association with PI3K/AKT signaling.
BENC-511 induces MM cell death in vivo and delays tumor growth in myeloma xenograft models
To check whether tumor decrease was associated with PI3K inhibition and apoptosis induced by BENC-511, tumor tissue extracts were subject to immunoblotting analyses. The results showed that both PARP and Caspase-3 were markedly cleaved in BENC-511 treated mice (Figure 7B). To our expectation, AKT phosphorylation was significantly suppressed in tumors from BENC-511-treated mice (Figure 7C). p70S6K and mTOR phosphorylation was also decreased in the same pattern as AKT (Figure 7D). However, BENC-511 had no changes in total protein levels in AKT, p70S6K, or mTOR (Figure 7). These data thus further demonstrated that BENC-511 was effective in the treatment of MM both in vitro and in vivo, which was highly associated with the suppression of the PI3K/AKT signaling pathway by BENC-511.
BENC-511 displays minimal toxicity in vivo
Toxicology of BENC-511 in nude mice: hematology analysis
1.81 ± 0.65
7.54 ± 1.37
110.00 ± 18.80
511.92 ± 134.68
1.70 ± 0.50
8.18 ± 1.97
123.80 ± 29.78
530.50 ± 112.82
Toxicology of BENC-511 in nude mice: biochemical analysis
62 (29.3 to 94.7)
237.7 (214.1 to 261.2)
10.3 (9.0 to 11.5)
10.7 (7.9 to 13.5)
48.2 (35.3 to 61.1)
189 (170.8 to 207.2)
11.3 (8.9 to 13.7)
12.4 (11.2 to 13.6)
The above study demonstrated that BENC-511 was significantly improved in terms of its activity to suppress PI3K/AKT activation, to induce MM cell apoptosis, and to delay tumor growth in vivo. Because of the minimal toxicity and great potency in the treatment of MM in vitro and in vivo, BENC-511 has a great potential for MM treatment.
S14161 has been demonstrated as a pan-PI3K inhibitor, which has no effects on PI3K associated enzymes including AKT, mTOR, PDK1 or GSK-3β. Cell-based and mice-based studies showed that S14161 could be a good candidate for leukemia and myeloma treatment. However, the presence of the chiral structural 4-fluorophenyl group at the chromene brings more work in its preparation and safety evaluation. Thalidomide, the then-best drug for morning sick, turned to be a teratogen which results in thousands of malformed babies due to the less knowledge in the chiral structure [29–31]. Now it is clear that in the two enatiomers of thalidomide, the “R” enantiomer is a relatively safe drug with sedative attributes, while the “S” enantiomer has devastating effects such as teratogenicity [32, 33]. Therefore, to improve the efficacy and to reduce the potential safety issue, we synthesized a series of analogs of S14161. The enzymatic assay revealed that the phenyl group is not important because when the whole fluorophenyl group is removed, the resultant QDF-510 and BENC-511 remain active in suppressing PI3K. Therefore, this structural optimization demonstrated that the 4-fluorophenyl group on chromene is dispensable for this class of PI3K inhibitors.
Beyond our prediction, removal of the phenyl ring increases but not decreases the suppressive activity of S14161 in PI3K inhibition because 4 μM of BENC-511 completely suppresses AKT activation within 24 hours, however, it was not markedly affected by S14161 in the same time frame. In the short-term treatment, a certain level of AKT phosphorylation remains at 100 μM within 2 hours, which is similar to LY294002, the classic pan-PI3K inhibitor [34, 35]. In contrast, BENC-511 almost suppressed AKT phosphorylation at 50 μM within 30 minutes.
Although other residues could be phosphorylated in AKT, its activation mainly depends on two sites, T308 and S473 , and T308 activation is mediated by PI3K via the phosphatidylinositol 3-kinase-dependent kinase 1 (PDK1) and it leads to activation of mTOR complex 1 (TORC1) in which mTOR activation occurs at S2448. Our study clearly demonstrated that BENC-511 inhibited AKT activation at T308 which suggests that BENC-511 probably inhibits PI3K activity. Phosphorylation on S473 facilitates fully activation of AKT, but BENC-511 can inhibit AKT at both T308 and S473 sites, therefore, BENC-511 fully inhibits AKT activation.
PI3K/AKT is the center node of a pyramid of cell signaling pathways including mTOR, p70S6K, 4E-BP1, and GSK-3β signals. mTOR is a serine/threonine protein kinase that regulates PI3K/AKT signals and is frequently referred to as the PI3K/AKT/mTOR signaling pathway . Investigations on PI3K/AKT signaling found that PI3K/AKT inhibition leads to suppressed activation of its downstream signals mTOR, p70S6K, and 4E-BP1 . BENC-511 has no inhibitory effects on AKT and mTOR in the cell-free based enzymatic assays but potently suppresses AKT and mTOR phosphorylation in cultured cells, suggesting that BENC-511 inhibits PI3K activation. p70S6K is a kinase that activates the S6 ribosomal protein thus inducing protein synthesis . 4E-BP1 is a repressor of protein translation and its phosphorylation lifts its repression function . Both p70S6K and 4E-BP1 phosphorylation are regulated by the PI3K/AKT signaling [39, 40]. In contrast to p70S6K and 4E-BP1, GSK-3β is negatively regulated by the PI3K/AKT signaling. The effects of BENC-511 on these signals are consistent with its effect on PI3K/AKT, which further suggests that BENC-511 inhibits the PI3K signaling pathway.
The PI3K/AKT signaling pathway is important for MM cell proliferation, survival and anti-apoptosis, downregulation of PI3K activity leads to MM cell death and decreased proliferation. In agreement with its potent activity on PI3K, BENC-511 is more effective than S14161 in inducing MM cell apoptosis. Notably, this apoptosis induced by BENC-511 could be partly attenuated by PI3K activation upon treatment with IL-6 or IGF-1, two key factors of PI3K signaling stimulation and key survival factors for MM cells, which further demonstrates that BENC-511 induces MM apoptosis by targeting the PI3K signaling pathway. Impressively, the anti-myeloma activity of BENC-511 is also proven in myeloma xenograft models. More than 75% inhibition on MM tumor growth in two different models by oral administration suggests that BENC-511 is highly efficacious. Importantly, activation of PI3K activity indicators AKT, mTOR, and p70S6K are also significantly decreased by BENC-511 in myeloma tumor tissues excised from experimental mice, which was accompanied by Caspase-3 activation. Collectively, all these findings demonstrated that BENC-511 not only induces apoptosis but also delays tumor growth in MM xenografts, which is associated with its inhibition on PI3K signals.
In summary, we developed BENC-511 as a more potent PI3K inhibitor than its parental compound by structural optimization. Because of its minimal toxicity and high efficacy, BENC-511 could be developed as a potent orally active anti-myeloma agent, but further safety evaluation should be performed.
Materials and methods
MM cell lines LP1, OCI-MY5, OPM2, and JJN3 were kindly provided by Dr. Aaron Schimmer from Ontario Cancer Institute, Toronto, Canada. RPMI-8226 and U266 were purchased from American Type Culture Collection (Washington, DC, USA). Human bone marrow stromal cell line HS-5 was generously provided by Prof. Lin Yang, the Cyrus Tang Hematology Center, Soochow University. All cell lines were maintained in Iscove’s modified Dulbecco medium (Hyclone), supplemented with 10% fetal bovine serum, 100 μg/ml penicillin, and 100 U/mL streptomycin (Hyclone Laboratories, Logan, UT).
Preparation of S14161 and its analogs
8-Ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene (S14161) was synthesized using the domino oxa-Michael-Henry reactions of salicylaldehyde with β-nitrostyrene . As shown in Figure 1A, WQD-612 had a replacement of the fluoro substituent with a hydrogen atom at the para position of the 2-phenyl ring in S14161, while DQJ-610 and DJY-611 had an electron-withdrawing cyano group and electron-donating methoxy substituent at the same position, respectively. Since S14161 has one chiral center in its structure and it was used as a racemate in its biological studies, we further simplified its structure by removing the 4-fluorophenyl group at the 2-position of the chromene core, which generated the 8-ethoxy-3-nitro-2H-chromene (QDF-510) and 6-bromo derivative BENC-511 .
AKT phosphorylation analysis
Multiple myeloma cell lines were maintained overnight in Iscove’s modified Dulbecco’s medium containing 0.5% fetal bovine serum, and treated with 100 μM of S14161 or BENC-511 for 0.5 to 2 hours before stimulation with 100 ng/mL human recombinant insulin-like growth factor-1(IGF-1, PeproTech, Rocky Hill, NJ) or 50 ng/mL of interleukin-6 (IL-6, Novoprotein, Summit, NJ) for 15 minutes before being lysed in a RIPA buffer containing 1 mM orthovanadate . After clarification, cell lysates were subjected to Western blotting analysis with anti-phospho-AKT (S473) or anti-AKT.
Cell growth and viability
Myeloma cell lines were plated at a density of 1 × 104 cells per well in 96-well plates (Wuxi Nest Biotechnology Co., Ltd, Wuxi, China). Cells were treated with BENC-511 with the increasing concentrations. Cell viability was evaluated by MTT assay as described previously .
PRMI-8226, LP1, OPM2, OCI-MY5 cells were treated with BENC-511 (0.5, 1 μM) or S14161 (1 μM) for 24 hour using DMSO as a control. Apoptosis was measured by staining cells with Annexin V-Fluorescein Isothiocyanate (annexin V-FITC) and propidium iodide (PI, Sigma) according to the manufacturers’ instruction. Stained cells were analyzed on a flow cytometer (FACSCalibur, Becton Dickinson).
Whole cell lysates were prepared as described previously . After proteins were then transferred to polyvinylidene difluoride membranes, the blots were then probed with antibodies including monoclonal PARP, Caspase-3, p-AKT(S473), p-AKT(T308), AKT, p-mTOR(S2448), Raptor, p-P70S6K, P70S6K, p-4E-BP1(S65), 4E-BP1 (all were purchased from Cell Signaling Technology, Inc.). GAPDH was purchased from Abgent. β-actin, anti–mouse immunoglobulin G (IgG) and anti–rabbit IgG horseradish peroxidase conjugated antibody were purchased from R&D Systems.
Multiple myeloma xenograft models
Human multiple myeloma cells (OPM2 and RPMI-8226) were injected subcutaneously into the right flanks of nude mice (5–6 weeks old, female, Shanghai Slac Laboratory Animal Co. Ltd., Shanghai) respectively. When tumors were palpable, mice were randomly divided into two groups (n = 10/group). One group was given BENC-511 (50 mg/kg body weight) in PBS containing 10% Tween 80 and 10% DMSO daily for 20 days, another group was received the vehicle only. Tumor volumes (tumor length × width2 × 0.5236) were measured over time with a caliper . Mouse body weight was also monitored every other day. To analyze protein signals from the tumor tissues at the end of the experiment, tumors were excised and snap-frozen immediately in liquid nitrogen. Tissue samples were then minced and homogenized to extract whole cell lysates. The clarified supernatants were applied for Western blotting analyses using specific antibodies.
Blood physiochemical assays
At the end of the experiment, whole blood samples were collected from the eyes and were immediately subject to complete blood analysis including the white blood cell (WBC), red blood cell (RBC), platelets (PLT) and haemoglobin (HGB) measurement on an automated hematology analyzer (Sysmex KX-21N, Japan). All samples were analyzed within 30 minutes after collection. At the same time, blood sera were isolated by centrifugation at 3,000 × g for 10 minutes and frozen for further analysis. Liver function was evaluated with serum levels of physiochemical indexes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) and creatinine (Cr). All biochemical assays were performed using a clinical automatic chemistry analyzer (Suzhou Municipal Hospital, Suzhou, China).
Data are presented as mean values with 95% confidence intervals (CIs) unless otherwise indicated. For in vivo studies, the Mann–Whitney rank sum nonparametric method was used to test for differences between treatment groups in the weight of the tumors. The t test was used for comparisons of two groups in the in vitro studies. All statistical tests were two-sided, and a P value less than 0.05 was considered statistically significant.
This work was partly supported by the National Natural Science Foundation of China (81071935, 81101795, 81272632, 81320108023), the Natural Science Foundation of Jiangsu Province (BK2010218, BK2011268), by the National Basic Research Program of China (2011CB933501) and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD). The study sponsors were not involved in the design, performance, analysis, and writing of the report.
- Czech MP: PIP2 and PIP3: complex roles at the cell surface. Cell. 2000, 100 (6): 603-606. 10.1016/S0092-8674(00)80696-0.View ArticlePubMedGoogle Scholar
- Cantrell DA: Phosphoinositide 3-kinase signalling pathways. J Cell Sci. 2001, 114 (Pt 8): 1439-1445.PubMedGoogle Scholar
- Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H: Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. J Hematol Oncol. 2012, 5: 16-10.1186/1756-8722-5-16.PubMed CentralView ArticlePubMedGoogle Scholar
- Shenker BJ, Ali H, Boesze-Battaglia K: PIP3 regulation as promising targeted therapy of mast-cell-mediated diseases. Curr Pharm Des. 2011, 17 (34): 3815-3822. 10.2174/138161211798357926.View ArticlePubMedGoogle Scholar
- Akinleye A, Avvaru P, Furqan M, Song Y, Liu D: Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013, 6 (1): 88-10.1186/1756-8722-6-88.PubMed CentralView ArticlePubMedGoogle Scholar
- Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2 (7): 489-501. 10.1038/nrc839.View ArticlePubMedGoogle Scholar
- Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C, Schultz PG, Reddy VA: The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA. 2009, 106 (1): 268-273. 10.1073/pnas.0810956106.PubMed CentralView ArticlePubMedGoogle Scholar
- Polak R, Buitenhuis M: The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood. 2012, 119 (4): 911-923. 10.1182/blood-2011-07-366203.View ArticlePubMedGoogle Scholar
- Fang X, Zhou X, Wang X: Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma. Biomark Res. 2013, 1 (1): 30-10.1186/2050-7771-1-30.PubMed CentralView ArticlePubMedGoogle Scholar
- Li J, Zhu J, Cao B, Mao X: The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma. Curr Pharm Des. 2014, 20 (1): 125-35. 10.2174/13816128113199990638.View ArticlePubMedGoogle Scholar
- Mao X, Cao B, Wood TE, Hurren R, Tong J, Wang X, Wang W, Li J, Jin Y, Sun W et al: A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood. 2011, 117 (6): 1986-1997. 10.1182/blood-2010-05-284810.View ArticlePubMedGoogle Scholar
- Falasca M: PI3K/Akt signalling pathway specific inhibitors: a novel strategy to sensitize cancer cells to anti-cancer drugs. Curr Pharm Des. 2010, 16 (12): 1410-1416. 10.2174/138161210791033950.View ArticlePubMedGoogle Scholar
- Courtney KD, Corcoran RB, Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010, 28 (6): 1075-1083. 10.1200/JCO.2009.25.3641.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu P, Hu YZ: PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress. Curr Med Chem. 2010, 17 (35): 4326-4341. 10.2174/092986710793361234.View ArticlePubMedGoogle Scholar
- Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005, 4 (12): 988-1004. 10.1038/nrd1902.View ArticlePubMedGoogle Scholar
- Bianchi G, Kumar S, Ghobrial IM, Roccaro AM: Cell trafficking in multiple myeloma. Open J Hematol. 2012, 3 (Suppl 1): 1-17.View ArticleGoogle Scholar
- Sutherlin DP, Baker S, Bisconte A, Blaney PM, Brown A, Chan BK, Chantry D, Castanedo G, DePledge P, Goldsmith P et al: Potent and selective inhibitors of PI3Kdelta: obtaining isoform selectivity from the affinity pocket and tryptophan shelf. Bioorg Med Chem Lett. 2012, 22 (13): 4296-4302. 10.1016/j.bmcl.2012.05.027.View ArticlePubMedGoogle Scholar
- Zhang J, Choi Y, Mavromatis B, Lichtenstein A, Li W: Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway. Oncogene. 2003, 22 (40): 6289-6295. 10.1038/sj.onc.1206718.View ArticlePubMedGoogle Scholar
- Ramakrishnan V, Kimlinger T, Haug J, Painuly U, Wellik L, Halling T, Rajkumar SV, Kumar S: Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS One. 2012, 7 (11): e50005-10.1371/journal.pone.0050005.PubMed CentralView ArticlePubMedGoogle Scholar
- Hsu J, Shi Y, Krajewski S, Renner S, Fisher M, Reed JC, Franke TF, Lichtenstein A: The AKT kinase is activated in multiple myeloma tumor cells. Blood. 2001, 98 (9): 2853-2855. 10.1182/blood.V98.9.2853.View ArticlePubMedGoogle Scholar
- Meadows SA, Vega F, Kashishian A, Johnson D, Diehl V, Miller LL, Younes A, Lannutti BJ: PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood. 2011, 119 (8): 1897-1900.View ArticlePubMedGoogle Scholar
- Brachmann SM, Kleylein-Sohn J, Gaulis S, Kauffmann A, Blommers MJ, Kazic-Legueux M, Laborde L, Hattenberger M, Stauffer F, Vaxelaire J et al: Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. Mol Cancer Ther. 2012, 11 (8): 1747-1757. 10.1158/1535-7163.MCT-11-1021.View ArticlePubMedGoogle Scholar
- Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC: Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012, 8 (5): 623-633. 10.1517/17425255.2012.681376.PubMed CentralView ArticlePubMedGoogle Scholar
- Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A, Takahashi H, Wakasugi T, Funahashi H, Sato M, Takeyama H: IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. J Surg Res. 2010, 160 (1): 90-101. 10.1016/j.jss.2008.08.016.View ArticlePubMedGoogle Scholar
- Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D: Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010, 95 (5): 819-828. 10.3324/haematol.2009.013797.PubMed CentralView ArticlePubMedGoogle Scholar
- Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B: Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 2010, 115 (22): 4455-4463. 10.1182/blood-2009-10-251082.PubMed CentralView ArticlePubMedGoogle Scholar
- Rodon J, Dienstmann R, Serra V, Tabernero J: Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013, 10 (3): 143-153. 10.1038/nrclinonc.2013.10.View ArticlePubMedGoogle Scholar
- Guo YQ, Chen SL: [The significance of IGF-1, VEGF, IL-6 in multiple myeloma progression]. Zhonghua Xue Ye Xue Za Zhi. 2006, 27 (4): 231-234.PubMedGoogle Scholar
- Shannon EJ, Morales MJ, Sandoval F: Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology. 1997, 35 (3): 203-212. 10.1016/S0162-3109(96)00149-X.View ArticlePubMedGoogle Scholar
- Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P et al: Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000, 96 (9): 2943-2950.PubMedGoogle Scholar
- Shimazawa R, Sano H, Tanatani A, Miyachi H, Hashimoto Y: Thalidomide as a nitric oxide synthase inhibitor and its structural development. Chem Pharm Bull (Tokyo). 2004, 52 (4): 498-499. 10.1248/cpb.52.498.View ArticleGoogle Scholar
- Hashimoto Y: Structural development of biological response modifiers based on thalidomide. Bioorg Med Chem. 2002, 10 (3): 461-479. 10.1016/S0968-0896(01)00308-X.View ArticlePubMedGoogle Scholar
- Richardson P, Anderson K: Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol. 2004, 22 (16): 3212-3214. 10.1200/JCO.2004.05.984.View ArticlePubMedGoogle Scholar
- Foukas LC, Berenjeno IM, Gray A, Khwaja A, Vanhaesebroeck B: Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc Natl Acad Sci USA. 2010, 107 (25): 11381-11386. 10.1073/pnas.0906461107.PubMed CentralView ArticlePubMedGoogle Scholar
- Ghigo A, Damilano F, Braccini L, Hirsch E: PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Bioessays. 2010, 32 (3): 185-196. 10.1002/bies.200900150.View ArticlePubMedGoogle Scholar
- Hart JR, Vogt PK: Phosphorylation of AKT: a mutational analysis. Oncotarget. 2011, 2 (6): 467-476.PubMed CentralView ArticlePubMedGoogle Scholar
- Markman B, Dienstmann R, Tabernero J: Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget. 2010, 1 (7): 530-543.PubMed CentralView ArticlePubMedGoogle Scholar
- Chung J, Kuo CJ, Crabtree GR, Blenis J: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. Cell. 1992, 69 (7): 1227-1236. 10.1016/0092-8674(92)90643-Q.View ArticlePubMedGoogle Scholar
- Gingras AC, Kennedy SG, O’Leary MA, Sonenberg N, Hay N: 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 1998, 12 (4): 502-513. 10.1101/gad.12.4.502.PubMed CentralView ArticlePubMedGoogle Scholar
- She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, Rosen N: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell. 2010, 18 (1): 39-51. 10.1016/j.ccr.2010.05.023.PubMed CentralView ArticlePubMedGoogle Scholar
- Yin SQ, Shi M, Kong TT, Zhang CM, Han K, Cao B, Zhang Z, Du X, Tang LQ, Mao X et al: Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro. Bioorg Med Chem Lett. 2013, 23 (11): 3314-3319. 10.1016/j.bmcl.2013.03.097.View ArticlePubMedGoogle Scholar
- Ling C, Chen G, Chen G, Zhang Z, Cao B, Han K, Yin J, Chu A, Zhao Y, Mao X: A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo. Int J Cancer. 2012, 131 (10): 2411-2419. 10.1002/ijc.27504.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.